0 0 0 0 0 0 -0.00793650793650794 -0.0158730158730159
Sign Up Today X
Thanks for submitting the form.
Stockreport

Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, non-Hodgkin's lymphoma, especially aggressive types like diffuse large B-cell lymphoma, represents a significant health burden. CAR T-Cell therapy is emerging as a potential cure, achieving over 50% complete response rates in clinical trials. The market's growth is further supported by FDA-approved therapies such as Yescarta, Kymriah, and Breyanzi, and a focus on next-generation CAR T innovations, including dual-targeted and allogeneic platforms. Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global CAR T-Cell therapy market for non-hodgkin's lymphoma (NHL) is witnessing a robust expansion, driven by a convergence of clinical innovation, rising dis [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Clinical Trials Boost CAR T-Cell Therapy as Efficacy Sparks Major Approvals for Non-Hodgkin's Lymphoma [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
and the pressing need for effective treatments in relapsed cases. Affecting over 500,000 individuals annually, non-Hodgkin's lymphoma, especially aggressive types like diffuse large B-cell lymphoma, represents a significant health burden. CAR T-Cell therapy is emerging as a potential cure, achieving over 50% complete response rates in clinical trials. The market's growth is further supported by FDA-approved therapies such as Yescarta, Kymriah, and Breyanzi, and a focus on next-generation CAR T innovations, including dual-targeted and allogeneic platforms. Dublin, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global CAR T-Cell therapy market for non-hodgkin's lymphoma (NHL) is witnessing a robust expansion, driven by a convergence of clinical innovation, rising dis [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS